F2G raises $60.8M to get new class of antifungal to market

F2G thinks its latest round of venture funding should be enough to carry its lead product onto the market, where it could become the first new antifungal in two decades, according to the company.

New investor Cowen Healthcare Investments led the $60.8 million round for  F2G Ltd., which told BioCentury that the new capital would finance completion of a Phase IIb trial of olorofim (formerly F901318), as well as a Phase III program and the therapy’s launch. ...